We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study.
- Authors
Valachis, Antonis; Carlqvist, Peter; Ma, Yuanjun; Szilcz, Máté; Freilich, Jonatan; Vertuani, Simona; Holm, Barbro; Lindman, Henrik
- Abstract
<bold>Background: </bold>Breast cancer is the most common cancer among women in Sweden. Whereas survival for the overall breast cancer population is well-documented, survival of patients with metastatic breast cancer (MBC) is harder to quantify due to the lack of reliable data on disease recurrence in national cancer registers.<bold>Methods: </bold>This study used machine learning to classify the total MBC population in Sweden diagnosed between 2009 and 2016 using national registers, with the aim to estimate overall survival (OS).<bold>Results: </bold>The total population consisted of 13,832 patients-2528 (18.3%) had de novo MBC whereas 11,304 (81.7%) were classed as having a recurrent MBC. Median OS for patients with MBC was found to be 29.8 months 95% confidence interval (CI) [28.9, 30.6]. Hormone-receptor (HR)-positive MBC had a median OS of 37.0 months 95% CI [35.9, 38.3] compared to 9.9 months 95% CI [9.1, 11.0] for patients with HR-negative MBC.<bold>Conclusion: </bold>This study covered the entire MBC population in Sweden during the study time and may serve as a baseline for assessing the effect of new treatment strategies in MBC introduced after the study period.
- Subjects
SWEDEN; CANCER relapse; CELL receptors; RETROSPECTIVE studies; BREAST tumors; OVERALL survival
- Publication
British Journal of Cancer, 2022, Vol 127, Issue 4, p720
- ISSN
0007-0920
- Publication type
journal article
- DOI
10.1038/s41416-022-01845-z